Échéancier de négociation

  • Initiation

    A drug is identified and brought into a pCPA process (see standard negotiation process or expedited negotiation pathways).

  • Consideration

    The pCPA considers the evidence (including HTA reimbursement recommendations) and gathers other data to inform the negotiation approach, in alignment with the needs of public drug plans. This phase concludes when the pCPA sends a letter of engagement to the manufacturer. 

    Letter of engagement sent to manufacturer

    This lets the manufacturer know the pCPA is ready to start negotiating.

  • Negotiation

    The pCPA negotiation team reaches out to the manufacturer to outline next steps, then we exchange offers to try to reach an agreement on terms and funding conditions.

  • Completion

    The pCPA creates a letter of intent outlining negotiated terms. If the negotiation ended without an agreement, the pCPA sends a letter letting the manufacturer know that the negotiation is closed. 

    Negotiation process concluded

Négociations connexes

Keytruda (pembrolizumab)

État:

Négociation conclue par une lettre d’intention

Fabricant:

Merck Canada Inc.

Indication:

For the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery.

Dernière mise à jour le:

25 avril 2025

Keytruda (pembrolizumab)

État:

Négociation conclue par une lettre d’intention

Fabricant:

Merck Canada Inc.

Indication:

For the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, in combination with carboplatin and paclitaxel and then continued as monotherapy.

Dernière mise à jour le:

24 juin 2025

Keytruda (pembrolizumab)

État:

Négociation conclue par une lettre d’intention

Fabricant:

Merck Canada Inc.

Indication:

In combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).

Dernière mise à jour le:

24 juillet 2025

Keytruda (pembrolizumab)

État:

Négociation conclue par une lettre d’intention

Fabricant:

Merck Canada Inc.

Indication:

For the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT).

Dernière mise à jour le:

23 octobre 2025